What is TB-500 and how does it relate to thymosin beta 4?
TB-500 is the common research-market label for a synthetic peptide derived from thymosin beta 4 (Tβ4), one of the beta-thymosin family of small, highly conserved intracellular peptides. Thymosin beta 4 is well documented as a major actin-sequestering peptide, and its structural and binding behaviour has been reviewed across several decades of biochemistry (PMID:12852258; PMID:4088087). The beta-thymosins as a class were characterised in detail by Hannappel and colleagues, who described their sequence conservation and abundance in mammalian tissues (PMID:17468232). More recent structural work has resolved the conformational states these peptides adopt when free versus actin-bound (PMID:27450728), and expression surveys have mapped Tβ4 distribution across human organs during development (PMID:38994967). For the purposes of buying research-grade material in Australia, the important point is chemical: the product should be characterised as a defined amino acid sequence with a known theoretical monoisotopic and average mass. A supplier's ability to demonstrate that the material in the vial matches that expected sequence — by mass spectrometry and orthogonal chromatography — is a legitimate cost input. When you see wide price gaps between listings, the difference frequently reflects whether the vendor performed and documented this identity work, or simply resold undocumented material. Understanding the peptide's identity at this level lets you interpret a CoA rather than trust a headline number. All of this framing is analytical and structural only; no biological outcome is implied for any species.
What analytical factors actually drive TB-500 price in Australia?
The price of research-grade TB-500 in Australia is built from a stack of measurable quality-control steps, each with a real laboratory cost. The largest single driver is chromatographic purity: reversed-phase HPLC with UV/diode-array detection quantifies the main peak against related substances, and a higher documented purity (for example ≥98% area) generally requires more extensive preparative purification and tighter acceptance criteria. Peak purity assessment using diode-array spectral comparison confirms the main peak is not co-eluting with an impurity, which adds analytical time. Identity confirmation by electrospray or MALDI-TOF mass spectrometry verifies the molecular weight matches the target sequence. Beyond purity and identity, net peptide content matters: a lyophilised powder contains counterions (commonly trifluoroacetate or acetate) and residual water, so the actual peptide mass per vial is lower than the gross fill weight. Counterion analysis and Karl Fischer water-content determination let a laboratory correct for this, and vendors who quantify it are selling a known quantity rather than an assumed one. Additional testing — related-substance profiling, residual solvent screening and, where relevant, endotoxin assessment — each contributes to the final price. When comparing Australian listings, a very low price often signals that some of these steps were skipped or outsourced without documentation. A defensible TB-500 price should be traceable to a specific analytical package, not just a milligram figure. This is why two vials labelled identically can differ substantially in cost and in the confidence a researcher can place in them.
How do you read a TB-500 certificate of analysis before buying?
A certificate of analysis is the document that converts a price into evidence, and reading it properly is the best way to compare TB-500 offers in Australia. Start with the identity section: it should state the peptide sequence, the theoretical average and monoisotopic mass, and the observed mass from mass spectrometry, with the two agreeing within instrument tolerance. Next, examine the HPLC purity result — look for the method (column chemistry, mobile-phase gradient, detection wavelength), the reported main-peak area percent, and ideally a chromatogram so you can judge baseline resolution and integration. A purity figure with no visible chromatogram or method detail is difficult to verify. Check whether peak purity or spectral homogeneity was assessed, which strengthens the claim that the main peak is a single component. The content section should report net peptide content with counterion and water-content corrections, so you know how much actual peptide the vial holds. Finally, confirm batch traceability: a unique lot number, manufacture or test date, and the analytical instruments used. Cross-referencing the lot number on the vial against the CoA closes the traceability loop. Our TB-500 analytical characterisation and CoA-interpretation resources walk through each of these fields with worked examples. A well-populated CoA justifies a higher price because it lets a laboratory reproduce and defend its material selection; a sparse CoA leaves the buyer carrying unquantified risk regardless of how attractive the headline price appears.
Why does the research literature affect how TB-500 is characterised?
The depth of published work on thymosin beta 4 shapes the analytical expectations placed on TB-500 material, because a well-studied peptide has established reference points for identity and structure. Thymosin beta 4 has been investigated across numerous experimental contexts — including coronary vessel development and neovascularisation in cardiac models (PMID:17495252; PMID:27450736), roles described in hepatic and fibrosis-related cell systems (PMID:27450733; PMID:26006229), ocular surface research programmes (PMID:30063853; PMID:27450739), actin regulation under sepsis conditions (PMID:29508629), hair-follicle biology in animal models (PMID:27130465; PMID:26083021), and emerging investigations in kidney and neurodegeneration research (PMID:41570941; PMID:40816274). These citations are provided strictly to indicate that the peptide is an extensively studied research subject, not to imply any outcome for any purchaser or species. The relevance to buying is analytical: because Tβ4's sequence, mass and structural behaviour are so well documented (PMID:27450728), a supplier has clear, literature-anchored targets against which to verify synthetic TB-500. A vendor that references the correct sequence and confirms the expected mass is aligning its material to the established biochemical record. When you evaluate an Australian TB-500 listing, the presence of accurate structural and identity information — consistent with the peer-reviewed literature — is a marker of analytical seriousness that a bare price cannot convey.
How do local Australian stock and dispatch change the total cost?
Headline price is only part of the total cost of acquiring research-grade TB-500 in Australia, and locally held stock materially changes the equation. Material dispatched from within Australia avoids international customs handling and the associated clearance delays that can leave a lyophilised peptide in transit for extended and poorly documented periods. Shorter, tracked domestic dispatch means the time between leaving controlled storage and arriving at a laboratory is minimised and recorded, which supports cleaner chain-of-custody documentation for the receiving researcher. Lyophilised peptides are generally more robust than reconstituted solutions, but transit time and handling still matter for stability records, so tracked dispatch with a documented lot reduces uncertainty. A locally supplied vial also arrives with its batch documentation intact and matched to the specific lot, rather than as anonymous repackaged material. When you compare an Australian TB-500 price against a cheaper overseas listing, factor in clearance risk, the absence of matched batch documentation, and the difficulty of resolving a query about an untraceable lot. A slightly higher domestic price that includes per-lot analytical documentation, a unique lot number and tracked local dispatch frequently represents lower total cost and lower research risk. For laboratories that must justify their material selection, that documentation trail — not the lowest sticker price — is what makes the purchase defensible in a research record.
Order Tb 500 with documentation
If this guide helped you evaluate Tb 500 for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Tb 500 card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Why do TB-500 prices vary so much between Australian suppliers?
Price variation usually reflects differing analytical packages. A vial backed by HPLC purity, mass spectrometry identity, counterion and water-content correction, and full batch documentation costs more to produce than undocumented resold material. Comparing certificates of analysis, not headline figures, reveals whether a lower price simply omitted verification steps.
What should a TB-500 certificate of analysis include?
Look for the peptide sequence, theoretical and observed mass by mass spectrometry, an HPLC purity result with method detail and ideally a chromatogram, peak-purity assessment, net peptide content corrected for counterion and water, and a unique lot number with test date. These fields let you verify identity and quantity rather than assume them.
Is TB-500 the same as thymosin beta 4?
TB-500 is a research-market label for a synthetic peptide derived from thymosin beta 4, a well-characterised beta-thymosin. The parent peptide's sequence, mass and actin-binding structure are extensively documented in the literature, which gives suppliers clear analytical targets for verifying synthetic material by chromatography and mass spectrometry.
Does buying TB-500 locally in Australia affect quality documentation?
Locally held stock with tracked domestic dispatch supports cleaner chain-of-custody records because material spends less time in undocumented international transit and arrives with batch documentation matched to its specific lot. This traceability is a quality and cost factor beyond the sticker price.
What is net peptide content and why does it affect price?
A lyophilised vial contains counterions and residual water, so actual peptide mass is lower than gross fill weight. Karl Fischer water determination and counterion analysis quantify this, giving a corrected net content. Vendors who measure and document it are selling a known quantity, which is a legitimate contributor to price.
References
- PMID:12852258 — Thymosin beta 4 interactions — Vitam Horm — 2003
- PMID:17468232 — beta-Thymosins — Ann N Y Acad Sci — 2007
- PMID:27450728 — Structures of Thymosin Proteins — Vitam Horm — 2016
- PMID:4088087 — Thymosin beta 4 — Methods Enzymol — 1985
- PMID:38994967 — Thymosin β(4) and β(10) Expression in Human Organs during Development: A Review — Cells — 2024
- PMID:17495252 — Thymosin beta-4 is essential for coronary vessel development and promotes neovascularization via adult epicardium — Ann N Y Acad Sci — 2007
- PMID:27450736 — Cardioprotection by Thymosin Beta 4 — Vitam Horm — 2016
- PMID:27450733 — Thymosin Beta 4 Is a Potential Regulator of Hepatic Stellate Cells — Vitam Horm — 2016
- PMID:26006229 — Potential role of thymosin Beta 4 in liver fibrosis — Int J Mol Sci — 2015
- PMID:30063853 — Thymosin beta 4 and the eye: the journey from bench to bedside — Expert Opin Biol Ther — 2018
- PMID:27450739 — Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy, Dry Eye, and Ocular Surface Diseases — Vitam Horm — 2016
- PMID:29508629 — Thymosin beta 4 regulation of actin in sepsis — Expert Opin Biol Ther — 2018
- PMID:27130465 — Role of thymosin beta 4 in hair growth — Mol Genet Genomics — 2016
- PMID:26083021 — Thymosin Beta-4 Induces Mouse Hair Growth — PLoS One — 2015
- PMID:41570941 — Thymosin beta 4: An emerging therapeutic candidate for kidney diseases — Peptides — 2026
- PMID:40816274 — Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids — Stem Cell Reports — 2025
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
